Coherus Oncology (CHRS) Interest Coverage Ratio (2013 - 2026)
Coherus Oncology's (CHRS) quarterly Interest Coverage Ratio came in at 13.92 in Q2 2026, up 30.33% year-over-year from 10.68 in Q2 2025, and up 15.84% quarter-over-quarter from 16.54 in Q1 2026.
Powered by 
Analysis
Coherus Oncology (CHRS) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed Interest Coverage Ratio across 14 years of filings, most recently posting 13.92 for Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 30.33% year-over-year to 13.92; the TTM figure through Jun 2026 stood at 17.47 (up 12.57% YoY), while the FY2025 annual figure was 20.12, down 8.19% from the prior year.
- Interest Coverage Ratio came in at 13.92 for Q2 2026 at Coherus Oncology, up from 16.54 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3.12 in Q3 2023 to a low of 23.74 in Q4 2024.
- Average Interest Coverage Ratio over 5 years is 13.04, with a median of 12.29 recorded in 2022.
- Year-over-year, Interest Coverage Ratio soared 70.79% in 2023 and plunged 431.73% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 5.49 in 2022, then slipped by 18.26% to 6.49 in 2023, then sank by 265.8% to 23.74 in 2024, then rose by 14.06% to 20.4 in 2025, then soared by 31.78% to 13.92 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 13.92 in Q2 2026, 16.54 in Q1 2026, and 20.4 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -13.92 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.92 |
| Mar 31, 2026 | -16.54 |
| Dec 31, 2025 | -20.40 |
| Sep 30, 2025 | -19.07 |
| Jun 30, 2025 | -19.98 |
| Mar 31, 2025 | -21.13 |
| Dec 31, 2024 | -23.74 |
| Sep 30, 2024 | -16.57 |
| Jun 30, 2024 | -9.76 |
| Mar 31, 2024 | -21.74 |
| Dec 31, 2023 | -6.49 |
| Sep 30, 2023 | -3.12 |
| Jun 30, 2023 | -3.47 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -5.49 |
| Sep 30, 2022 | -10.67 |
| Jun 30, 2022 | -6.69 |
| Mar 31, 2022 | -9.02 |
| Dec 31, 2021 | -6.83 |
| Sep 30, 2021 | -5.68 |